checkpoint inhibitors

Displaying 1 - 5 of 5

Encephalitis identified as rare toxicity of immunotherapy treatment

After a cancer patient receiving an immunotherapy developed encephalitis and died 18 months into treatment, researchers at Vanderbilt-Ingram Cancer Center (VICC) investigated why the complication occurred, performing a molecular analysis of the disease’s pathology and mining data to determine the incidence of similar occurrences.

Related Categories: 
Research cancer immunotherapy checkpoint inhibitors Department of Medicine douglas johnson encephalitis Justin Balko Nature Medicine Vanderbilt Ingram Cancer Center

Discovery points to new cancer immunotherapy option

An international team involving Vanderbilt researchers has discovered that a new “checkpoint” protein on immune system cells is active in tumors, and that blocking it — in combination with other treatments — is a successful therapeutic approach in mouse models of cancer.

Related Categories: 
Amy and Barry Baker Lab cancer immunotherapy Cancer Research checkpoint inhibitors department of otolaryngology Flow Cytometry Shared Resource immune system immunotherapy t cell Vanderbilt Ingram Cancer Center Vanderbilt Institute for Infection Immunology and Inflammation Young Kim

Breast cancer-killing RIG

Immune checkpoint inhibitors — cancer therapies that remove the “brakes” on the adaptive anti-tumor immune response — have had remarkable success in melanoma and lung cancer.

Related Categories: 
Health and Medicine Research antivirus Basic Sciences breast cancer cancer cancer biology immunotherapy Cancer Research checkpoint inhibitors Department of Cell and Developmental Biology immune response national science foundation Rebecca Cook Vanderbilt Ingram Cancer Center

Immunotherapies linked to specific heart complications

Immunotherapies linked to specific heart complications

Related Categories: 
adverse drug reactions cancer immunotherapy cancer checkpoint inhibitors Department of Medicine douglas johnson immunotherapy James C. Bradford Jr. Melanoma Fund Javid Moslehi NCI NIH The Lancet Oncology Vanderbilt Cardio-Oncology Vanderbilt Ingram Cancer Center

Study tracks incidence, timing of immunotherapy-related deaths

Study tracks incidence, timing of immunotherapy-related deaths

Related Categories: 
checkpoint inhibitors douglas johnson immunotherapy JAMA Oncology NIH Vanderbilt Ingram Cancer Center